Inventiva S.A. (IVA.PA)
EUR 2.15
(2.38%)
EUR 2.15
(2.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -101.84 Million EUR | -84.7% |
| 2022 | -57.11 Million EUR | -22.46% |
| 2021 | -52.27 Million EUR | -56.93% |
| 2020 | -31.77 Million EUR | -8.09% |
| 2019 | -28.35 Million EUR | 11.29% |
| 2018 | -32.04 Million EUR | -65.15% |
| 2017 | -21.99 Million EUR | -89.49% |
| 2016 | -11.14 Million EUR | 24.3% |
| 2015 | -13.9 Million EUR | -14.07% |
| 2014 | -12.42 Million EUR | -10.93% |
| 2013 | -11.41 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -51.81 Million EUR | 0.0% |
| 2023 Q2 | -53.86 Million EUR | 0.0% |
| 2023 FY | - EUR | -84.7% |
| 2023 Q4 | -47.98 Million EUR | 0.0% |
| 2022 Q4 | -23.38 Million EUR | 0.0% |
| 2022 Q2 | -35.82 Million EUR | 0.0% |
| 2022 FY | - EUR | -22.46% |
| 2021 Q2 | -13.43 Million EUR | -39.39% |
| 2021 Q1 | -9.63 Million EUR | 36.69% |
| 2021 FY | - EUR | -56.93% |
| 2021 Q4 | -30.22 Million EUR | 0.0% |
| 2020 FY | - EUR | -8.09% |
| 2020 Q1 | -6.46 Million EUR | 40.02% |
| 2020 Q2 | -8.52 Million EUR | -31.92% |
| 2020 Q4 | -15.22 Million EUR | 0.0% |
| 2019 FY | - EUR | 11.29% |
| 2019 Q4 | -10.77 Million EUR | 0.0% |
| 2019 Q2 | -20.95 Million EUR | -192.76% |
| 2019 Q1 | -7.15 Million EUR | 59.38% |
| 2018 Q4 | -17.62 Million EUR | 0.0% |
| 2018 FY | - EUR | -65.15% |
| 2018 Q2 | -14.41 Million EUR | -85.74% |
| 2018 Q1 | -7.76 Million EUR | 33.55% |
| 2017 FY | - EUR | -89.49% |
| 2017 Q1 | -4.8 Million EUR | 14.74% |
| 2017 Q2 | -10.31 Million EUR | -114.88% |
| 2017 Q4 | -11.67 Million EUR | 0.0% |
| 2016 Q4 | -5.63 Million EUR | 0.0% |
| 2016 Q2 | -5.51 Million EUR | -102.21% |
| 2016 Q1 | -2.72 Million EUR | 58.43% |
| 2016 FY | - EUR | 24.3% |
| 2015 FY | - EUR | -14.07% |
| 2015 Q4 | -6.55 Million EUR | -91.21% |
| 2015 Q3 | -3.42 Million EUR | 53.34% |
| 2015 Q2 | -7.34 Million EUR | -114.34% |
| 2015 Q1 | -3.42 Million EUR | 0.0% |
| 2014 FY | - EUR | -10.93% |
| 2014 Q2 | -2.87 Million EUR | 0.0% |
| 2014 Q1 | -2.87 Million EUR | 0.0% |
| 2014 Q3 | -2.87 Million EUR | 0.0% |
| 2014 Q4 | -3.42 Million EUR | -19.37% |
| 2013 Q3 | -2.58 Million EUR | 0.0% |
| 2013 Q1 | -2.58 Million EUR | 0.0% |
| 2013 Q4 | -2.87 Million EUR | -11.18% |
| 2013 FY | - EUR | 0.0% |
| 2013 Q2 | -2.58 Million EUR | 0.0% |
| 2012 Q4 | -2.58 Million EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -2995.684% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 23.542% |
| Adocia SA | -22.73 Million EUR | -348.038% |
| Aelis Farma SA | -6.34 Million EUR | -1504.664% |
| Biophytis S.A. | -13.8 Million EUR | -637.815% |
| Advicenne S.A. | -6.24 Million EUR | -1531.134% |
| genOway Société anonyme | 6.35 Million EUR | 1703.716% |
| IntegraGen SA | -52.5 Thousand EUR | -193885.106% |
| Medesis Pharma S.A. | -3.84 Million EUR | -2548.923% |
| Neovacs S.A. | -8.44 Million EUR | -1105.367% |
| NFL Biosciences SA | -4.04 Million EUR | -2415.199% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 140521.894% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -3444.413% |
| Sensorion SA | -22.31 Million EUR | -356.435% |
| Theranexus Société Anonyme | -7.38 Million EUR | -1278.703% |
| TME Pharma N.V. | -5.07 Million EUR | -1908.044% |
| Valbiotis SA | -6.95 Million EUR | -1364.385% |
| TheraVet SA | -517.33 Thousand EUR | -19587.012% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -438.422% |
| argenx SE | -199.5 Million EUR | 48.95% |
| BioSenic S.A. | -6.79 Million EUR | -1398.646% |
| Celyad Oncology SA | -7.76 Million EUR | -1211.967% |
| DBV Technologies S.A. | -79.53 Million EUR | -28.061% |
| Galapagos NV | 51.03 Million EUR | 299.557% |
| Genfit S.A. | -28.05 Million EUR | -263.082% |
| GeNeuro SA | -14.31 Million EUR | -611.343% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -579.893% |
| Innate Pharma S.A. | -7.57 Million EUR | -1243.996% |
| MaaT Pharma SA | -19.74 Million EUR | -415.947% |
| MedinCell S.A. | -20.04 Million EUR | -408.071% |
| Nanobiotix S.A. | -34.01 Million EUR | -199.386% |
| Onward Medical N.V. | -35.23 Million EUR | -189.062% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -2197.311% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | -337.755% |
| Oxurion NV | -16.72 Million EUR | -508.811% |
| Pharming Group N.V. | 4.98 Million EUR | 2144.744% |
| Poxel S.A. | -12.17 Million EUR | -736.259% |
| GenSight Biologics S.A. | -21.73 Million EUR | -368.698% |
| Transgene SA | -27.02 Million EUR | -276.88% |
| Financière de Tubize SA | 184.57 Thousand EUR | 55280.933% |
| UCB SA | 1.26 Billion EUR | 108.026% |
| Valneva SE | -64.51 Million EUR | -57.862% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | -259.214% |